Metraipolis › archive › dc_0d592daedc6c
Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and… — Europe PMC PMID:42388875
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42388875
- DOI
- 10.3389/fendo.2026.1843595
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T09:00:47.562Z
- SHA-256 of the archived text
1edfd7ea1e2c1c80b42868623c1236cf3c0a7e893e14537ffab1a626ef51783a- Stable URL of this page
https://metraipolis.com/documento/dc_0d592daedc6c
How to cite
Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and… — Europe PMC PMID:42388875 — Europe PMC (en), https://europepmc.org/article/MED/42388875 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0d592daedc6c (Metraipolis archive dc_0d592daedc6c, sha256 1edfd7ea1e2c1c80b42868623c1236cf3c0a7e893e14537ffab1a626ef51783a)
BibTeX
@misc{dc0d592daedc6c,
title = {Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and… — Europe PMC PMID:42388875},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42388875},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0d592daedc6c; sha256 1edfd7ea1e2c1c80b42868623c1236cf3c0a7e893e14537ffab1a626ef51783a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42388875. Agents can read the archived copy with the MCP tool read_document.